The activity of target nucleases is a hallmark of infections and other diseases that can be detected by designing specific and highly sensitive oligonucleotide probes that generate a response/signal when cleaved by the enzyme.
The detection of nuclease activity is the differential element that SOMAprobes exploits to develop its oligonucleotide probes. These probes are versatile and can be implemented on standard immunoassay platforms including lateral flow, point-of-care devices, and mid- and high-throughput platforms present in every hospital laboratory.
Biomarker discovery (Nuclease)
Oligonucleotide substrate characterization
Implementation of detection system
Applications of our technology
SOMAprobes’ technology enables a novel, differential and versatile IVD platform with broad application:
Our technology has the advantage of being easily adaptable to any immunoassay technique.
March 8, 2021
The start-up Somaprobes was founded in Guipúzcoa in 2014 by Frank Hernández and Luiza Hernández. This start-up aims to accelerate the diagnosis of diseases such as cancer or sepsis through rapid tests.
Among the different projects developed by this entity is a diagnostic technology based on nucleases. The surprise came when, with the appearance of COVID-19, the team detected that this virus had two genetic markers, one of them a nuclease. Research, work and motivation led them to what they know as Corona-test.
Ultra-Sensitive and Specific Detection of S. aureus Bacterial Cultures Using an Oligonucleotide Probe Integrated in a Lateral Flow-Based Device
The identification of pathogens causing infectious diseases is still based on laborious and time-consuming techniques. Therefore, there is an urgent need for the development of novel methods and devices that can considerably reduce detection times, allowing the health professionals to administer the right treatment at the right time. Lateral flow-based systems provide fast, cheap and easy to use alternatives for diagnosis. Herein, we report on a lateral flow approach for specifically detecting S. aureus bacteria within 6 h.
Discovery and Proof-of-Concept Study of Nuclease Activity as a Novel Biomarker for Breast Cancer Tumors
A diagnostic biomarker for the detection of breast cancer remains an unmet clinical need despite decades of intensive research efforts. Herein, we describe, for the first time, the use of nuclease activity as a biomarker to discriminate between healthy and cancer biopsy samples. We have identified a panel of three nucleic acid probes able to target nucleases derived from breast cancer tumors with high sensitivity and specificity. These results are in good agreement with histopathological analysis as the diagnostic gold standard.
We are the ﬁrst to postulate the nuclease activity derived from Salmonella as biomarker of infection and its utility to develop innovative detection strategies. Our results have shown the screening and identiﬁcation of two oligonucleotide sequences (substrates) as the most promising probes for detecting Salmonella e Sal-3 and Sal-5. The detection limits for both probes were determined with the reference Salmonella Typhimurium (STM 1) and Salmonella Enteritidis (SE 1) cultures.
We report on the activity of nucleases derived from cancer cells as a means for specific targeting using nucleic acid probes (substrates). We hypothesize that cancer cells can be diﬀerentiated from healthy cells based on their nuclease activity profile, and thus, any method based on this property represents a novel alternative for diagnostic and therapeutic intervention.